Oncternal Therapeutics to effect 1-for-20 reverse stock split

Oncternal Therapeutics board of directors has approved a 1-for-20 reverse stock split of the company’s common stock. The reverse stock split will become effective at 12:01 a.m. Eastern time on January 8, 2024. The company’s common stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market under the same symbol when the market opens on January 8, 2024 with the new CUSIP number 68236P206. The reverse stock split was approved by the company’s stockholders at its 2023 annual meeting, held on June 28, 2023, to be effected at the Board’s discretion with a ratio within the range of not less than 1-for-5 and not more than 1-for-30. As a result of the reverse stock split, every 20 shares of the company’s common stock issued and outstanding will be automatically converted into one share of common stock, with no change in the $0.001 par value per share or authorized number of shares of common stock. No fractional shares will be issued in connection with the reverse split and stockholders who would otherwise be entitled to a fractional share of common stock will instead be entitled to receive a proportional cash payment. The reverse stock split is primarily intended to bring the company into compliance with Nasdaq’s minimum bid price requirement. To regain compliance, the bid price of the company’s common stock must close at $1.00 per share or more for a minimum of ten consecutive business days.